Belite Bio Secures $402M in Public Offering, Reports Strong Cash Position, and Confirms Q2 2026 NDA Submission for Tinlarebant

summarizeSummary

Belite Bio announced the completion of a $402 million public offering, boosting its cash and investments to $772.6 million, and confirmed it is on track to submit an NDA for tinlarebant in Q2 2026.

check_boxKey Events

• Completed $402 Million Public Offering

  Belite Bio successfully completed an underwritten public offering of American Depositary Shares, raising $402 million in net proceeds to support commercialization preparation, pipeline development, and general corporate purposes.

• Strong Cash Position

  As of December 31, 2025, the company reported $352.9 million in cash and cash equivalents and $419.7 million in investments, totaling $772.6 million in liquidity, a significant increase from the prior year.

• NDA Submission for Tinlarebant on Track

  Following positive topline results from the pivotal Phase 3 DRAGON trial for Stargardt disease, the company remains on track to submit a New Drug Application (NDA) to the U.S. FDA in Q2 2026.

• Clinical Trial Enrollment Completed

  Enrollment was completed for both the Phase 2/3 DRAGON II trial in adolescent STGD1 patients and the Phase 3 PHOENIX trial in Geographic Atrophy (GA) patients, indicating continued pipeline advancement.

auto_awesomeAnalysis

Belite Bio has significantly strengthened its financial position by completing a substantial $402 million public offering. This capital infusion, combined with existing funds, provides the company with a robust cash runway of $772.6 million, crucial for a clinical-stage biotech. The confirmed timeline for submitting a New Drug Application (NDA) for tinlarebant in Q2 2026, following positive Phase 3 DRAGON trial results, marks a critical step towards potential commercialization for Stargardt disease. Additionally, the company reported continued progress in its clinical pipeline with completed enrollments for the DRAGON II and PHOENIX trials. This comprehensive update signals strong operational execution and financial stability, supporting the company's valuation as it trades near its 52-week high.